Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
RECOMBINANT FUSION PROTEIN TARGETING CD47 AND CD24, AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/061084
Kind Code:
A1
Abstract:
Provided is a recombinant fusion protein, comprising a CD24 antibody or an antibody fragment thereof. At least one paratope of the CD24 antibody or the antibody fragment thereof is linked to an extracellular Ig-like domain of a signal regulatory protein (SIRP) at an N-terminus of a heavy chain or a light chain forming the paratope by means of a linker, wherein the recombinant fusion protein can be combined with CD47, CD24 and FcR at the same time. Also provided are a nucleic acid molecule encoding the recombinant fusion protein, an expression vector comprising the nucleic acid molecule, a method for preparing the recombinant fusion protein, and a method for treating diseases associated with CD47 and/or CD24 overexpression by using the recombinant fusion protein.

More Like This:
JP3455228[Title of Invention] Chromosome 13 Chain-Breast Cancer Sensitivity Gene
WO/2011/097527IMMUNOPROTECTION OF THERAPEUTIC MOIETIES USING ENHANCED FC REGIONS
JP2762310[Title of the Invention] Synthetic peptides derived from Streptococcal M protein and vaccines prepared from the peptides.
Inventors:
TIAN WENZHI (CN)
LI SONG (CN)
CHEN DIANZE (CN)
Application Number:
PCT/CN2022/116315
Publication Date:
April 20, 2023
Filing Date:
August 31, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC (CN)
International Classes:
C07K19/00; A61K39/395; A61P35/00; A61P35/02; C12N15/62
Domestic Patent References:
WO2020102422A12020-05-22
Foreign References:
CN113956363A2022-01-21
CN113831412A2021-12-24
CN112533954A2021-03-19
CN108623689A2018-10-09
CN111278865A2020-06-12
CN112646043A2021-04-13
US20200048364A12020-02-13
Other References:
WU HAO, LIU JIALIN, WANG ZHIFEI, YUAN WEN, CHEN LING: "Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma", CNS NEUROSCIENCE & THERAPEUTICS, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 27, no. 10, 1 October 2021 (2021-10-01), GB , pages 1105 - 1117, XP055923914, ISSN: 1755-5930, DOI: 10.1111/cns.13714
BARKAL AMIRA A.; BREWER RACHEL E.; MARKOVIC MAXIM; KOWARSKY MARK; BARKAL SAMMY A.; ZARO BALYN W.; KRISHNAN VENKATESH; HATAKEYAMA J: "CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 572, no. 7769, 31 July 2019 (2019-07-31), London, pages 392 - 396, XP036861556, ISSN: 0028-0836, DOI: 10.1038/s41586-019-1456-0
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: PHASE-CHANGE MICROCAPSULE, SEPARATOR, ELECTRODE PLATE, BATTERY, AND ELECTRICAL DEVICE

Next Patent: CARD INFORMATION DISPLAY METHOD, ELECTRONIC DEVICE, AND GRAPHICAL USER INTERFACE